Rapport Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-24.3%projected annual EPS growth
Analyst Coverage
12analysts covering
FY Revenue (est.)
$20Mnext fiscal year
FY EPS (est.)
-$4.09next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
| RAP-219 Phase 2 Bipolar Mania Topline Data Readout | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
RAP-219 Phase 3 Focal Onset Seizures (FOS) Trial Initiation QuarterlyTarget: Initiation of FOCUS 1 and FOCUS 2 trials in Q2 2026
RAP-219 Phase 2 Bipolar Mania Topline Results QuarterlyTarget: Topline data readout in Q4 2026
Cash Runway Quarterly476.8MTarget: Fund operations into the second half of 2029
Watch Items
- RAP-219 Phase 3 FOS Trial Enrollment and ExecutionTrigger: Delays in patient recruitment or site activation across global sites (including China via Tenacia)Action: Re-evaluate clinical trial timelines, CRO performance, and capital allocation priorities.
- RAP-219 Phase 2 Bipolar Mania Topline DataTrigger: Failure to meet primary efficacy endpoints or emergence of safety/tolerability signals in Q4 2026Action: Assess the viability of the psychiatric franchise and focus resources strictly on the epilepsy portfolio.
- Competitor Clinical ReadoutsTrigger: Positive Phase 3 data or regulatory approvals for competing focal epilepsy assets (e.g., Xenon's azetukalner)Action: Review RAP-219's competitive positioning, market entry strategy, and commercial differentiation.
Research as of 20 Jun 2026